<DOC>
	<DOCNO>NCT01879722</DOCNO>
	<brief_summary>The purpose study characterize safety tolerability TAK-063 administer multiple oral dos escalate dose level participant stable schizophrenia healthy Japanese participant .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic Study Multiple Rising Doses TAK- 063 Participants With Stable Schizophrenia Healthy Participants</brief_title>
	<detailed_description>The drug test study call TAK-063 . TAK-063 test find well-tolerated dose also treat schizophrenia . This study look well different dos TAK-063 tolerate healthy people Japanese descent people stable schizophrenia . Five dose level examine , start low , population 10 participant dose level . These participant randomize receive TAK-063 ( 8 subject ) placebo ( 2 subject ) daily ( QD ) 7 day . In total , approximately 60 participant enrol study . This trial conduct single site United States . The overall time participate study 42 day . Participants make 2 visit clinic , include 8-10 day confinement clinic , contact telephone 7 day last dose study drug follow-up assessment . Dose escalation actual choice subsequent dose level occur follow review blind data previous cohort .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Healthy Participants : 1 . Aged 2055 year , inclusive , time informed consent first study medication dose . 2 . Is healthy adult male female Japanese descent ( bear Japanese parent grandparent live outside Japan le 5 year ) . 3 . Weighs least 45 kg body mass index ( BMI ) 18.0 28.0 kg/m^2 , inclusive , Screening . Participants Stable Schizophrenia : 1 . Is age 18 55 year , inclusive , time informed consent first study medication dose . 2 . Is adult male female diagnosis schizophrenia schizoaffective disorder . 3 . Weighs least 45 kg BMI 18.0 35.0 kg/m^2 , inclusive Screening . 4 . Has receive stable dose antipsychotic monotherapy least 1 month prior Screening . 5 . Has acute exacerbation psychosis hospitalization treatment schizophrenia schizoaffective disorder least 3 month prior Screening . All Participants : 1 . Has uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , endocrine disease abnormality ( disease study ) , may impact ability participant participate potentially confound study result . 2 . If female , participant pregnant lactate intend become pregnant , intend donate ovum , , course study within 12 week last dose . 3 . Intends donate sperm course study 12 week last dose . 4 . Has evidence current cardiovascular , central nervous system , hepatic , hematopoietic disease , renal dysfunction , metabolic endocrine dysfunction , serious allergy , asthma hypoxemia , hypertension , seizure , allergic skin rash . There find participant 's medical history , physical examination , safety laboratory test give reasonable suspicion disease would contraindicate take TAK063 , similar drug class , might interfere conduct study . This include , limited , peptic ulcer disease , seizure disorder , cardiac arrhythmia . Healthy Participants : 1 . Has history treatment Axis I/II mental disorder accord Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) depression , anxiety disorder , bipolar disorder , attention deficit hyperactivity disorder ( ADHD ) , autism spectrum disorder , anorexia nervosa , bulimia nervosa schizophrenia within past 3 year . 2 . Has use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin Day 1 . Cotinine test positive Screening Checkin ( Day 1 ) . Participants Stable Schizophrenia : 1 . Has history primary DSMIV axis I diagnosis schizophrenia schizoaffective disorder . 2 . Has discontinue antipsychotic psychotropic medication unable discontinue antipsychotic psychotropic medication Day 7 ( five halflives prior Day 1 ) . 3 . Is take concomitant medication medical condition stable dose regimen less two month take concomitant medication medical condition less two month discontinuation study period medically permissible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>